Your session is about to expire
← Back to Search
Ruxolitinib + Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Study Summary
This trial will compare the different tyrosine kinase inhibitors, with and without ruxolitinib, to see how well they work in treating patients with chronic myeloid leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 149 Patients • NCT02038036Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My BCR-ABL levels are between 0.0032% and 1.0% as confirmed by a recent test.I am currently on treatment with specific targeted cancer drugs.My heart's electrical activity is normal as per my recent EKG.I have been on TKI treatment for my CML for at least a year.I have never had a drug resistance to TKI medication.I had a full medical check-up in the last 28 days.My white blood cell count is healthy.My blood samples were sent to a certified lab within the last 21 days.I have had cancer before, but it doesn't need current treatment.I agree to provide samples for future research.I agree to use effective birth control during and for 30 days after treatment.I have chronic myeloid leukemia in the chronic phase without it worsening.
- Group 1: Arm I (bosutinib, dasatinib, nilotinib, imatinib)
- Group 2: Arm II (ruxolitinib phosphate, dasatinib, nilotinib, imatinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there multiple research sites conducting this investigation in North America?
"This study, which currently has 100 slots open for enrolment, is recruiting at the Vince Lombardi Cancer Clinic-Sheboygan in Sheboygan, Oregon Health and Science University in Portland, Swedish Cancer Institute-Edmonds in Edmonds, amongst other medical centres."
Could you provide a synopsis of past research involving Ruxolitinib Phosphate?
"Currently, 185 clinical trials are running to explore the effects of Ruxolitinib Phosphate. Among those studies, 25 have progressed to Phase 3 and over 7500 different sites worldwide are recruiting for these experiments. Specifically, Fukuoka City in Japan holds a plethora of such research initiatives."
How many participants are being included in this trial?
"This clinical trial mandates the involvement of 84 participants with qualifying characteristics. At Vince Lombardi Cancer Clinic-Sheboygan in Sheboygan, Wisconsin and Oregon Health and Science University in Portland, Oregon, potential candidates can join this medical research project."
What sort of risks does Ruxolitinib Phosphate pose to individuals undergoing treatment?
"The safety of Ruxolitinib Phosphate has been estimated as a 2 on our company's scale, due to the clinical evidence that exists supporting its security but not yet demonstrating effectiveness."
Is this experiment actively searching for new participants?
"As detailed on the clinicaltrials.gov website, recruitment is in progress for this medical research trial which was initially posted on October 24th 2018 and amended as recently as May 3rd 2022."
What conditions is Ruxolitinib Phosphate typically employed to treat?
"Ruxolitinib Phosphate is known to be a viable treatment option for polycythemia vera. Patients with hydroxyurea-resistant or -intolerant polycythemia, as well as those struggling with primary myelofibrosis, can also benefit from this medication."
Share this study with friends
Copy Link
Messenger